BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) has provided an update on its flagship sublingual Cladribine drug formulation program for Multiple Sclerosis (MS) treatment. The company reported positive results from animal toxicity and pharmacokinetics studies, with plans for a human comparative bioequivalence study in early Q1 2025.
BioNxt also announced a positive international examination report from the European Patent Office for its patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases. The company expects EU patent grant within four weeks and plans to file in other major jurisdictions.
Additionally, BioNxt confirmed Myasthenia Gravis as its second clinical indication using anticancer compounds in a sublingual drug delivery system. The company has also engaged two consultants for investor relations activities starting October 1, 2024, for a six-month period.
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) ha fornito un aggiornamento sul suo programma di formulazione del farmaco Cladribina sublinguale per il trattamento della Sclerosi Multipla (SM). L'azienda ha riportato risultati positivi dagli studi di tossicità su animali e farmacocinetica, con piani per uno studio umano comparativo di bioequivalenza all'inizio del primo trimestre del 2025.
BioNxt ha anche annunciato un rapporto d'esame internazionale positivo da parte dell'Ufficio Brevetti Europeo per la sua domanda di brevetto riguardante la somministrazione sublinguale di farmaci anticancro per le malattie neurodegenerative autoimmuni. L'azienda prevede di ottenere il brevetto dell'UE entro quattro settimane e pianifica di presentare domande in altre giurisdizioni importanti.
Inoltre, BioNxt ha confermato la Miastenia Grave come sua seconda indicazione clinica utilizzando composti anticancro in un sistema di somministrazione sublinguale. L'azienda ha anche ingaggiato due consulenti per attività di relazioni con gli investitori a partire dal 1° ottobre 2024, per un periodo di sei mesi.
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) ha proporcionado una actualización sobre su programa de formulación del fármaco Cladribina sublingual para el tratamiento de la Esclerosis Múltiple (EM). La empresa informó resultados positivos de estudios de toxicidad en animales y farmacocinética, con planes para un estudio humano comparativo de bioequivalencia a principios del primer trimestre de 2025.
BioNxt también anunció un informe de examen internacional positivo de la Oficina Europea de Patentes para su solicitud de patente sobre la entrega sublingual de medicamentos anticancerígenos para enfermedades neurodegenerativas autoinmunes. La empresa espera la concesión de la patente de la UE en un plazo de cuatro semanas y planea presentar en otras jurisdicciones importantes.
Adicionalmente, BioNxt confirmó la Miastenia Gravis como su segunda indicación clínica utilizando compuestos anticancerígenos en un sistema de entrega sublingual de medicamentos. La empresa también ha contratado a dos consultores para actividades de relaciones con inversores a partir del 1 de octubre de 2024, por un período de seis meses.
BioNxt 솔루션즈 Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT)는 다발성 경화증(MS) 치료를 위한 설하 클라드리빈 약물 제형 프로그램에 대한 업데이트를 제공했습니다. 회사는 동물 독성 및 약동학 연구에서 긍정적인 결과를 보고했으며, 2025년 1분기 초에 인간 비교 생물학적 동등성 연구 계획을 세우고 있습니다.
BioNxt는 또한 자가 면역 신경퇴행성 질환을 위한 항암제의 설하 투여에 대한 특허 신청에 대해 유럽 특허청에서 긍정적인 국제 심사 보고서를 발표했습니다. 회사는 4주 이내에 EU 특허를 받을 것으로 예상하고 있으며, 다른 주요 관할권에서도 신청할 계획입니다.
추가로, BioNxt는 항암 화합물을 사용한 두 번째 임상 적응증으로 중증 근무력증을 확인했습니다. 회사는 2024년 10월 1일부터 6개월 동안 투자자 관계 활동을 위한 두 명의 컨설턴트를 모집했습니다.
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) a fourni une mise à jour sur son programme phare de formulation de médicament sublingual Cladribine pour le traitement de la Sclérose en plaques (SEP). L'entreprise a rapporté des résultats positifs d'études de toxicité animale et de pharmacocinétique, avec des plans pour une étude de bioéquivalence humaine comparative au début du premier trimestre 2025.
BioNxt a également annoncé un rapport d'examen international positif de l'Office Européen des Brevets pour sa demande de brevet concernant l'administration sublinguale de médicaments anticancéreux pour les maladies neurodégénératives auto-immunes. L'entreprise s'attend à obtenir le brevet de l'UE dans un délai de quatre semaines et prévoit de déposer des demandes dans d'autres juridictions majeures.
De plus, BioNxt a confirmé la Myasthénie grave comme sa deuxième indication clinique utilisant des composés anticancéreux dans un système de délivrance de médicaments sublinguaux. L'entreprise a également engagé deux consultants pour des activités de relations investisseurs à partir du 1er octobre 2024, pour une durée de six mois.
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) hat ein Update zu seinem führenden sublingualen Cladribin-Arzneimittelprogramm zur Behandlung von Multipler Sklerose (MS) bereitgestellt. Das Unternehmen berichtete über positive Ergebnisse aus Tierversuchen zur Toxizität und Pharmakokinetik und plant eine human vergleichende Bioäquivalenzstudie zu Beginn des ersten Quartals 2025.
BioNxt kündigte außerdem einen positiven internationalen Prüfbericht vom Europäischen Patentamt für seinen Patentantrag zur sublingualen Abgabe von Antikrebsmitteln für autoimmune neurodegenerative Erkrankungen an. Das Unternehmen erwartet innerhalb von vier Wochen die Erteilung des EU-Patents und plant, in anderen großen Jurisdiktionen zu beantragen.
Darüber hinaus bestätigte BioNxt Myasthenia Gravis als seine zweite klinische Indikation, bei der Antikrebsmittel in einem sublingualen Arzneimittelsystem eingesetzt werden. Das Unternehmen hat außerdem zwei Berater für Investorenbeziehungen engagiert, die am 1. Oktober 2024 für einen Zeitraum von sechs Monaten beginnen.
- Positive results from animal toxicity and pharmacokinetics studies for sublingual Cladribine formulation
- Planned human comparative bioequivalence study for Q1 2025
- Positive international examination report from European Patent Office for sublingual anticancer drug delivery patent
- Expected EU patent grant within four weeks
- Plans to file patents in multiple major international jurisdictions
- Expansion into Myasthenia Gravis as second clinical indication for sublingual anticancer drug delivery system
- None.
VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment of Multiple Sclerosis ("MS"), broad sublingual patent application for the use of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, and investor relations activities.
BioNxt's lead program is the development of a
In the first half of 2024, the Company announced positive results for both its sublingual Cladribine animal toxicity study and animal pharmacokinetics ("PK") studies. The animal toxicity study results demonstrated zero adverse clinical abnormalities or indications of toxicity in any participants after consecutive days of dosing. The PK study results demonstrated highly comparable rapid absorption and bioequivalence between the Company's sublingual product and the name-brand reference drug for all administered samples. The next steps in the development and commercialization process include technology and process transfer, upscaling of manufacturing capability, analytical method development and validation, and clinical sample manufacturing preparation, manufacturing, and product release for use in the human comparative bioequivalence study planned for early Q1 2025. The bioequivalence study will be carried out with a European contract research organization in accordance with EU medical regulatory guidelines.
On September 9, 2024, BioNxt reported that the European Patent Office ("EPO") issued a positive international examination report for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, such as MS. The Company expects the EU patent to be granted within four weeks and to rapidly enter the national phase of the Patent Cooperation Treaty ("PCT") patent process with submissions planned for the US, Canada, China, Japan, Australia, and other jurisdictions.
BioNxt plans to continue development of and extend its patent portfolio regarding sublingual drug products containing highly potent anticancer compounds for neurodegenerative diseases. The Company intends to file several related provisional patent applications in the EU with three to four patents expected to be on file in multiple major international jurisdictions by late 2025 to early 2026 with potential patent protection extending to 2045.
Further to the Company's MS program, BioNxt confirms that its second clinical indication using anticancer compounds in a sublingual drug delivery system will be Myasthenia Gravis ("MG"). MG is an autoimmune and neuromuscular disease characterised by muscle weakness and fatigue. MG patients also commonly experience Dysphagia whereby a sublingual product is expected to yield a significant advantage over conventional tablet forms. The global MG market is expected to reach USD 6.7 billion by 2032 according to Clinical Trials Arena.
In general, the expectation of continued increasing prevalence of Central Nervous System ("CNS") pathologies will drive investment into new drugs and new drug delivery systems capable of targeting these diseases. The market size for drugs to treat CNS diseases is growing and expected to reach USD 238.8 billion by 2032 according to GMI Market Insights.
BioNxt is also pleased to report that it has engaged two individual consultants (the "Consultants") to provide Promotional Activity pursuant to Policy 7 of the Canadian Securities Exchange for a period of six months commencing on October 1, 2024. The investor relations activities will include working to increase the shareholder base, market liquidity, and share price through distribution of company information and direct communication with contacts in their respective investor networks, including qualified investors, investment advisors, financial analysts, newsletter writers, and media outlets. Each of the Consultants, Rob Grace, Delta, Canada, and Lance Fortt, Angus, Australia, will receive 12,500 CAD cash per month, 500,000 share purchase options exercisable into common shares of the Company at
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
FAQ
What is BioNxt's main drug development program for Multiple Sclerosis?
When is BioNxt planning to conduct the human comparative bioequivalence study for sublingual Cladribine?
What is the status of BioNxt's patent application for sublingual delivery of anticancer drugs?
What is BioNxt's second clinical indication for its sublingual drug delivery system?